08.28.13
A double-blind, randomized, placebo-controlled clinical study published in the Journal of Food Research (Vol.2, No.5; 2013 by Canadian Center of Science and Education) investigated the effects of SesaVita (branded ingredient of Olive Lifesciences and standardized extract of Sesamum indicum) in the management of pre-diabetes and hyperlipidemia.
Dr. Shiva Prasad, vice president of Olive Lifesciences and author of published clinical study said, “Not only is the clinical data on SesaVita impressive, it also works in quite a unique way to reduce elevated blood glucose level and altered lipid profile in subjects who are advised with therapeutic lifestyle changes.” A statistical significant reduction was observed in low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), oral glucose tolerance test (OGTT) and fasting blood sugar (FBS) levels during week 3 and 6 when treated with SesaVita extract. No adverse events occurred and all safety parameters were within normal ranges during the study. For more information: www.olivelifesciences.com
Dr. Shiva Prasad, vice president of Olive Lifesciences and author of published clinical study said, “Not only is the clinical data on SesaVita impressive, it also works in quite a unique way to reduce elevated blood glucose level and altered lipid profile in subjects who are advised with therapeutic lifestyle changes.” A statistical significant reduction was observed in low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), oral glucose tolerance test (OGTT) and fasting blood sugar (FBS) levels during week 3 and 6 when treated with SesaVita extract. No adverse events occurred and all safety parameters were within normal ranges during the study. For more information: www.olivelifesciences.com